Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study

[1]  Y. Ko,et al.  Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial , 2005, The Lancet.

[2]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Morandi,et al.  Cardiac toxicity of high-dose chemotherapy , 2005, Bone Marrow Transplantation.

[5]  H. Hausmaninger,et al.  Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Shpall,et al.  Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer , 2004, Clinical Cancer Research.

[7]  C. Orlandini,et al.  HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support , 2004, Bone Marrow Transplantation.

[8]  E. Perez,et al.  Clinical cardiac tolerability of trastuzumab. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Gray,et al.  Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. , 2003, The New England journal of medicine.

[10]  S. Rodenhuis,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. , 2003, The New England journal of medicine.

[11]  F. Innocenti,et al.  High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine–epirubicin–paclitaxel in metastatic breast cancer: a dose finding study , 2003, Bone Marrow Transplantation.

[12]  D. Berry,et al.  Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Shpall,et al.  Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Sahin,et al.  HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[17]  J. Bergh,et al.  Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial , 2000, The Lancet.

[18]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[19]  E. Shpall,et al.  Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  Terry L. Smith,et al.  Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. , 2000, Journal of the National Cancer Institute.

[21]  C. Orlandini,et al.  Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Czuczman,et al.  Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  B. Samuels,et al.  Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  P. Viens,et al.  High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study. , 2005, Anticancer research.

[25]  T. Delozier,et al.  High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. , 2005, European journal of cancer.

[26]  B. Asselain,et al.  High-dose chemotherapy for breast cancer: the French PEGASE experience. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[27]  C. Orlandini,et al.  High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Amela,et al.  CONVENTIONAL-DOSE CHEMOTHERAPY COMPARED WITH HIGH-DOSE CHEMOTHERAPY PLUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR METASTATIC BREAST CANCER , 2000 .

[29]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.